Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?
Nazia Chaudhuri,1 Vincent Cottin,2 Stefania Cerri,3 Michael Kreuter,4 Maria Otaola,5 Diego Castillo Villegas,6 Craig Glazer,7 Heiko Müller,8 Carl Coeck,9 Toby M Maher10 on behalf of the INBUILD trial investigators
1North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, UK; 2National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, Lyon, France; 3Center for Rare Lung Disease - Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy; 4Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany; 5Fundación para el Estudio de Enfermedades Fibrosantes del Pulmón, Buenos Aires, Argentina; 6Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 7Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA; 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 9SCS Boehringer Ingelheim Comm.V., Brussels, Belgium; 10National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Introduction
- In the INBUILD trial in subjects with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (other than idiopathic pulmonary fibrosis [IPF]), nintedanib slowed the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by 57% versus placebo.1
- Subgroup analyses suggested that the effect of nintedanib on reducing the rate of decline in FVC was consistent across subgroups with different ILD diagnoses.2
- Autoimmune rheumatic diseases are commonly treated using disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids.